专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

91. 发明申请

WO2007044669A3 ENGINEERED BIOLOGICAL MATRICES 审中-公开
公开(公告)号：WO2007044669A3
公开(公告)日：2007-04-19
申请号：PCT/US2006/039399
申请日：2006-10-06
申请人： CAMBREX BIO SCIENCE WALKERSVILLE, INC. , STEIN, Thomas, Mark , POWERS, Mark, James , COOPER, Jonathan, William , DAMIAN, Sorin , HUIBERTS, Pieter, Johannes, Dirk , GUISELEY, Kenneth, B.
发明人： STEIN, Thomas, Mark , POWERS, Mark, James , COOPER, Jonathan, William , DAMIAN, Sorin , HUIBERTS, Pieter, Johannes, Dirk , GUISELEY, Kenneth, B.
IPC分类号： A61L27/52
摘要： Biocompatible matrices or implants on which one or more specific cell-interactive molecules ("biomolecules") can be immobilized have been developed. The matrices allow for the independent control of ligand concentration and matrix strength. In one embodiment, the matrix or implant is modified with one or more moieties capable of complexing bioconjugates prepared from one or more biomolecules. Suitable moieties include phenyl boronic acid complexing agents, such as salicylhydroxamic acid, which can complex to one or more biomolecules containing one or more phenyl boronic acid moieties. The biomolecules may be anchored to the matrix via a spacer molecule, which may allow for greater mobility of the biomolecules in aqueous solution. In one embodiment, the matrix is a hydrogel material which has been doubly-derivatized, wherein ligand concentration and matrix strength can be independently controlled. The matrices and implants can be used in in vivo and in vitro applications including diagnostics, biosensors, bioprocess engineering, tissue engineering, regeneration and repair, and drug delivery.

92. 发明申请

WO2006138056A1 PHARMACEUTICAL COMPOSITION COMPRISING A MAHONIA AQUIFOLIUM EXTRACT FOR THE TREATMENT OF PSORIASIS 审中-公开
标题翻译：包含MAHONIA AQUIFOLLUM提取物治疗PSORIASIS的药物组合物
公开(公告)号：WO2006138056A1
公开(公告)日：2006-12-28
申请号：PCT/US2006/020855
申请日：2006-05-26
申请人： APOLLO PHARMACEUTICAL, INC. , GOMEZ, Hector, J.
发明人： GOMEZ, Hector, J.
IPC分类号： A61K36/29 , A61P17/00
CPC分类号： A61K36/29 , A61K31/00 , A61K31/366 , A61K31/4178 , A61K31/59 , A61K31/593 , A61K31/7034 , A61K31/7056 , A61K45/06 , A61K2300/00
摘要： Pharmaceutical compositions for the treatment of skin disorders such as psoriasis, acne and eczema, methods of making the compositions and methods of use thereof are described herein. The composition comprises psorberine, an alcohol-water extract isolated from the Mahonia aquifolium plant, and one or more additional active agents. In a preferred embodiment, the one or more active agents is a vitamin D3 analog, such as calcipotriol. The compositions may also contain excipients such as emollients, surfactants, emulsiflers and buffers. The compositions are formulated into a cream, lotion or ointment for topical administration.
摘要翻译：本文描述了用于治疗皮肤病如牛皮癣，痤疮和湿疹的药物组合物，制备组合物的方法和使用方法。所述组合物包含磷酸肌醇，从马蹄莲植物分离的醇 - 水提取物和一种或多种另外的活性剂。在优选的实施方案中，一种或多种活性剂是维生素D3类似物，例如卡泊三醇。组合物还可以含有赋形剂，例如润肤剂，表面活性剂，乳化剂和缓冲剂。将组合物配制成用于局部给药的乳膏，洗剂或软膏。

93. 发明申请

WO2006124988A3 TERMINAL STERILIZATION OF INJECTABLE COLLAGEN PRODUCTS 审中-公开
公开(公告)号：WO2006124988A3
公开(公告)日：2006-11-23
申请号：PCT/US2006/019064
申请日：2006-05-17
申请人： ALBIOREX, LLC , CHU, George , HARRELL, C., Randall , GOMEZ, Hector, J.
发明人： CHU, George , HARRELL, C., Randall , GOMEZ, Hector, J.
IPC分类号： A61L2/00
摘要： Methods of sterilizing dermal fillers and injectable collagen material have been developed which reduce the level of active biological contaminants or pathogens without adversely affecting the material, i.e., wherein the dermal fillers and injectable collagen material retain their same properties before and after its terminal sterilization. In one embodiment the method for sterilizing the dermal filler or injectable collagen material that is sensitive to radiation contains the steps of protecting the filler or material from radiation, and irradiating the filler or material with a suitable dose of radiation for a time and at a rate effective to sterilize the filler or injectable material. In a preferred embodiment the method for sterilizing the dermal filler or injectable collagen material that is sensitive to radiation includes the steps of a) freezing the filler or material at a temperature below its freezing temperature, which is generally below 0°C and b) irradiating the filler or material with a suitable dose of radiation at an effective rate for a time effective to sterilize the filler or material. The exposure of the radiation differs depending upon the density of the filler or material, but is preferably between 6kGy and 12kGy and more preferably between 6kGy and 8kGy. These doses result in a sterility assurance level (SAL) of 10 -6 SAL for the filler or material.

94. 发明申请

WO2006071813A2 DISPOSABLE MEDICAL SUPPLIES FROM HYDROLYTICALLY BIODEGRADABLE PLASTICS 审中-公开
标题翻译：一次性水性生物降解塑料的一次性医疗用品
公开(公告)号：WO2006071813A2
公开(公告)日：2006-07-06
申请号：PCT/US2005/046922
申请日：2005-12-22
申请人： DOMB, Abraham, J. , LANGER, Robert, S.
发明人： DOMB, Abraham, J. , LANGER, Robert, S.
IPC分类号： A61F13/53
CPC分类号： A61L29/148 , Y10T428/1352 , Y10T428/2913 , Y10T428/2915 , Y10T428/31786
摘要： Hydrolytically degradable polymers in the form of biodegradable disposable medical devices for use in medicine and laboratories such as syringes, test tubes, catheters, tubing, trays, medical fabrics, and gloves are described. The devices are formed in whole or in part of a hydrolytically degradable polymer. In the preferred embodiment, the devices or structural components thereof degrade in a period of weeks to months, preferably within a year and more preferably within six months of exposure to aqueous solutions. Conventional hydrolytically degradable polymers may be utilized or these may be modified to increase mechanical or processing characteristics, for example, using a polyfunctional branching agent and/or a chain extending agent. In one embodiment, the hydrolytically degradable polymer is a member of a class of polyesters comprising an aliphatic dicarboxylic acid, an aliphatic diol and optionally, one or more bifunctional fatty acids, such as ricinoleic acid and/or castor oil. The devices are prepared using standard techniques, such as by injection molding, extrusion or melt spinning. The devices can be formed entirely of the degradable polymer, or they can be coated with a polymer coating, optionally formed of a non-biodegradable polymer, in order to increase the compatibility of and reduce the possibility for interaction between the surface of the device and liquids that may come in contact with the device, or they may include core or other internal structural member formed of either the biodegradable or non-biodegradable material and a coating of either a biodegradable or non-biodegradable material.
摘要翻译：描述了用于医学和实验室的生物可降解一次性医疗装置形式的水解可降解聚合物，例如注射器，试管，导管，管道，托盘，医用织物和手套。该装置全部或部分由可水解降解的聚合物形成。在优选实施方案中，所述装置或其结构组分在暴露于水溶液的数周至数月内，优选在一年内，更优选在六个月内降解。可以使用常规的可水解降解的聚合物，或者可以对这些聚合物进行改性以增加机械或加工特性，例如使用多官能支化剂和/或扩链剂。在一个实施方案中，可水解降解的聚合物是包含脂族二羧酸，脂族二醇和任选地一种或多种双官能脂肪酸如蓖麻油酸和/或蓖麻油的一类聚酯的成员。这些装置使用标准技术制备，例如通过注塑，挤出或熔融纺丝。这些装置可以完全由可降解聚合物形成，或者它们可以涂覆有聚合物涂层，任选地由不可生物降解的聚合物形成，以便提高装置表面的相容性并降低装置表面与可能与设备接触的液体，或者它们可以包括由生物可降解或不可生物降解材料和可生物降解或不可生物降解材料的涂层形成的芯或其他内部结构构件。

95. 发明申请

WO2006047068A1 NON-BLOOMING GELATIN AND NON-GELATIN FORMULATIONS 审中-公开
标题翻译：不凝血凝胶和非凝胶制剂
公开(公告)号：WO2006047068A1
公开(公告)日：2006-05-04
申请号：PCT/US2005/036210
申请日：2005-10-07
申请人： BANNER PHARMACAPS, INC. , SUKURU, Karunakar , CHIDAMBARAM, Nachiappan , FATMI, Aqeel, A.
发明人： SUKURU, Karunakar , CHIDAMBARAM, Nachiappan , FATMI, Aqeel, A.
IPC分类号： A61K9/48
CPC分类号： A61K9/4816 , A61K9/4825 , A61K9/4858 , A61K9/4866
摘要： A non-blooming plasticizer composition and methods of using the composition are described herein. The composition is a mixture of sorbitol and sorbitan wherein the ratio of sorbitan and sorbitol is between about 0.40 and about 1.2 by weight, more preferably from about 0..45-0.50 to about 0.70 by weight, wherein the composition contains less than 20% of other dextrose hydrolytic degradation products. The non-blooming plasticizer compositions can be mixed, alone or in combination with other shell additives, with gelatin or non-gelatin materials to prepare soft capsules for the delivery of pharmaceutical, nutritional and personal care products, such as bath oils, shampoos and conditioners, and skin lotions.
摘要翻译：本文描述了未起霜的增塑剂组合物和使用该组合物的方法。组合物是山梨糖醇和脱水山梨糖醇的混合物，其中脱水山梨糖醇和山梨糖醇的比例为约0.40至约1.2重量比，更优选约0.45-0.50至约0.70，其中组合物含有小于20重量％的其他葡萄糖水解降解产物。未起霜的增塑剂组合物可以单独或与其它壳添加剂组合与明胶或非明胶材料混合以制备用于递送药物，营养和个人护理产品的软胶囊，例如沐浴油，洗发剂和调理剂，和皮肤洗剂。

96. 发明申请

WO2006029404A1 SYSTEM FOR CONTROL OF STICKIES IN RECOVERED AND VIRGIN PAPER PROCESSING 审中-公开
标题翻译：用于控制恢复和虚拟纸张处理中的纸张的系统
公开(公告)号：WO2006029404A1
公开(公告)日：2006-03-16
申请号：PCT/US2005/032487
申请日：2005-09-08
申请人： ENZYMATIC DEINKING TECHNOLOGIES, LLC , WANG, Xiang , MA, Jianhua , TAUSCHE, James, G.
发明人： WANG, Xiang , MA, Jianhua , TAUSCHE, James, G.
IPC分类号： D21H21/02
CPC分类号： D21H21/02 , D21C9/08 , D21H17/22 , D21H17/45 , D21H17/67 , D21H23/765
摘要： Enhanced removal and/or control of adhesives or sticky materials, "stickies", from recovered paper stock or virgin pulp fibers is achieved using a combination of enzyme treatment with adsorbents and/or absorbents. Pulp stock to be treated is typically obtained from old magazines, newspapers, household waste, but may include corrugated boxes and office waste. Virgin pulps may include mechanical, chemical, or semi-chemical pulps. Enzymes typically include hydrolases such as cellulases, hemicellulases, pectinases, amylases, and lipases such as esterases, lyases such as pectate lyases, and oxidoreductases. Adsorbents include activated bentonite, microparticles, talc, clay and modified silica. Absorbents typically include water soluble polymers, dispersants, coagulatants and agglomerants.
摘要翻译：使用酶处理与吸附剂和/或吸收剂的组合来实现从回收的纸料或原始纸浆纤维中增强粘合剂或粘性材料“粘性”的去除和/或控制。待处理的纸浆通常是从旧杂志，报纸，家庭垃圾中获得的，但可能包括瓦楞纸箱和办公室废物。处女纸可能包括机械，化学或半化学纸浆。酶通常包括水解酶如纤维素酶，半纤维素酶，果胶酶，淀粉酶和脂肪酶如酯酶，裂解酶如果胶酸裂合酶和氧化还原酶。吸附剂包括活性膨润土，微粒，滑石，粘土和改性二氧化硅。吸收剂通常包括水溶性聚合物，分散剂，凝结剂和附聚物。

97. 发明申请

WO2006020979A2 FACTOR VII CONJUGATES FOR SELECTIVELY TREATING NEOVASCULARIZATION DISORDERS 审中-公开
标题翻译：因子VII共轭选择性治疗新生血管性疾病
公开(公告)号：WO2006020979A2
公开(公告)日：2006-02-23
申请号：PCT/US2005/029017
申请日：2005-08-15
申请人： YALE UNIVERSITY , GAREN, Alan , ADELMAN, Ron, A. , HU, Zhiwei
发明人： GAREN, Alan , ADELMAN, Ron, A. , HU, Zhiwei
IPC分类号： A61K41/00 , A61P19/08 , A61P29/00 , A61P35/00 , A61P27/00
CPC分类号： A61K38/41 , A61K41/0071 , A61K47/64
摘要： Methods and compositions are provided for the treatment of diseases such as exudative macular degeneration, diabetic retinopathy, retinopathy of prematurity, choroidal neovascularization, retinal neovascularization, iris neovascularization, corneal neovascularization, ocular tumors, and other disorders of the eye, cancer, and inflammatory disorders. The method involves administering a conjugate, referred to as fVIIPD, containing a photosensitizer and a targeting molecule such as factor VII ("fVII"), fVIIa, or modified fVII, which binds with high affinity and specificity to tissue factor (TF). TF is more highly expressed, abnormally expressed or specifically expressed on endothelial cells lining the luminal surface of pathological neovasculature, than on normal vasculature, thus providing a specific and accessible therapeutic target. Following administration of fVIIPD, the compound specifically binds to the pathological neovasculature of the eye by interaction of the targeting molecule with TF expressed by endothelial cells within abnormal blood vessels. The photosensitizer may then be activated with a non-thermal laser light for selective destruction of abnormal vasculature.
摘要翻译：提供了用于治疗诸如渗出性黄斑变性，糖尿病性视网膜病，早产儿视网膜病，脉络膜新血管生成，视网膜新血管生成，虹膜新血管生成，角膜新血管生成，眼部肿瘤和其他病症的方法和组合物，眼睛，癌症和炎症性疾病。该方法包括施用含有光敏剂和靶向分子（例如因子VII（“fVII”），fVIIa或修饰的fVII）的结合物（称为fVIIPD），其以高亲和力和特异性与组织因子（TF）结合。 TF在病理性新血管系统的管腔表面上的内皮细胞上比在正常脉管系统中更高度表达，异常表达或特异性表达，从而提供特异性和可接近的治疗靶标。施用fVIIPD后，化合物通过靶向分子与异常血管内的内皮细胞表达的TF的相互作用特异性结合眼睛的病理性新血管系统。然后可以用非热激光激活光敏剂以选择性破坏异常脉管系统。

98. 发明申请

WO2006014646A3 METHODS FOR DIAGNOSIS USING ANTI-CYTOKINE RECEPTOR ANTIBODIES 审中-公开
公开(公告)号：WO2006014646A3
公开(公告)日：2006-02-09
申请号：PCT/US2005/025588
申请日：2005-07-20
申请人： EARLY DETECTION, LLC , ADCOCK, Deborah, Kay
发明人： ADCOCK, Deborah, Kay
IPC分类号： C12Q1/68
摘要： Labeled antibodies, antibody fragments or peptides binding to soluble cytokines or cytokine receptors are used to diagnose whether a patient has cancer or an autoimmune disease. In a preferred embodiment, a radiolabelled tag that is chemically bound to a peptide, antibody, or antibody fragment specific for sTNFR-1 and/or sTNFR2 is injected into a patient with a tumor, or suspected tumor, or with any disease associated with STNF1/STNF-2. The patient is then imaged using standard nuclear imaging equipment to detect areas or sites of concentration of the radiolabel and/or receptor/inhibitor and/or antigen. By screening for cancer by the substances it produces, using an injected antibody to that substance with a tracer attached to it, one can detect cancer at a very early stage, potentially even microscopically.

99. 发明申请

WO2005115358A3 INTRANASAL DELIVERY OF NUCLEIC ACID MOLECULES 审中-公开
公开(公告)号：WO2005115358A3
公开(公告)日：2005-12-08
申请号：PCT/US2005/015432
申请日：2005-05-04
申请人： YALE UNIVERSITY , LEE, Patty , ZHANG, Xuchen
发明人： LEE, Patty , ZHANG, Xuchen
IPC分类号： C12N15/11 , A61K31/713 , A61P11/00 , A61P3/00
摘要： Aerosol delivery of nucleic acids to the lungs using viral vectors, polymers, surfactants, or excipients has been described. Compositions for intranasal administration are described that contain nucleic acids without viral or plasmid vectors and with little to no polymers, surfactants, or excipients. In one embodiment, the composition for intranasal delivery consists essentially of at least one nucleic acid and an aqueous solution. Suitable nucleic acids for intranasal delivery include, but are not limited to, dsDNA, dsRNA, ssDNA, ssRNA, short interfering RNA, micro-RNA, and antisense RNA. Methods for treatment, diagnosis, or prevention of at least one symptom or manifestation of a lung disease are also described consisting of administration by intranasal delivery an effective amount of a composition containing a nucleic acid. The composition may be formulated as a liquid or aerosol or other acceptable formulation for intranasal administration.

100. 发明申请

WO2022240817A1 METHODS OF VISUALIZING DOPAMINE TRANSPORTERS 审中-公开
公开(公告)号：WO2022240817A1
公开(公告)日：2022-11-17
申请号：PCT/US2022/028502
申请日：2022-05-10
申请人： LIKEMINDS, INC.
发明人： KOENIG, Reinhard
IPC分类号： A61K51/04 , A61K51/0455 , A61K51/0468
摘要： Disclosed are methods of dopamine transporter (DaT) visualization in the brain of a subject (e.g., a subject suspected of suffering from Parkinson's disease, dementia with Lewy bodies, or Alzheimer's disease). The methods typically include the step of intravenous administration to the subject of a first dose of [123I]altropane and the step of acquiring SPECT counts from the subject's brain (e.g., obtaining a first number of SPECT counts of the subject's brain). If the first number of SPECT counts is less than the number indicating that a final SPECT image is obtainable within one SPECT session, then the subject is uptitrated using one or more intravenous administrations of [123I]altropane in the increments of, e.g., 0.5-3 mCi of [123I]altropane, until the number of acquired SPECT counts indicates that a final SPECT image may be obtained.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式